

Management Presentation Q1 2015 Financial Results 29 May, 2015



Disclaimer

You must read the following before continuing.

The following applies to the company presentation (the "company presentation") following this important notice, and you are therefore advised to read this important notice carefully before reading, accessing or making any other use of the company presentation. In accessing the company presentation, you agree to be bound by the following terms and conditions, including any modifications to them any time that you receive any information from us as a result of such access. The information contained in this company presentation has been prepared by Avangardco investments public limited ("Avangard" or the "company").

This document does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, Ukraine or the United States or in any jurisdiction to whom or in which such offer or solicitation is unlawful. This presentation is not an offer for sale of securities in the United States or any other jurisdiction. Any securities which are the subject of such offer have not been, and will not be, registered under the U.S. Securities act of 1933, as amended (the "securities act"), or the securities laws of any state of the United States or other jurisdiction and may not be offered or sold within the united states or to, or for the account or benefit of, U.S. Persons (as defined in regulation s under the securities act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the securities act and any applicable state or local securities laws. Any offer of such securities will be made by means of an offering document that will contain detailed information about the company and its management, including financial statements. Any investment decision should be made on the basis of the final terms and conditions of the securities and the information contained in such offering document and not on the basis of this presentation which does not constitute or form part of an offer or solicitation of an offer to purchase or subscribe for any securities. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada, Japan, or Ukraine or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada, Japan, or Ukraine. There will be no public offer of the securities at or under the applicable securities laws of Australia, Canada, Japan, or Ukraine. There will be no public offer of the securities in the United States.

This company presentation is only addressed to and directed at persons in member states of the European economic area who are "qualified investors" within the meaning of article 2(1)(e) of the prospectus directive (directive 2003/71/ec) ("qualified investors"). In addition, in the United Kingdom, this company presentation is being distributed only to, and is directed only at (i) investment professionals within the meaning set out in article 19(5) of the financial services and markets act 2000 (financial promotion) order 2005, as amended (the "order") and qualified investors falling within article 49(2)(a) to (d) of the order, and (ii) persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). This company presentation must not be acted on or relied on (i) in the United Kingdom, by persons who are not relevant persons, and (ii) in any member state of the European economic area other than the United Kingdom, by persons who are not qualified investors. Any investment or investment activity to which this company presentation relates is available only to (i) in the United Kingdom, relevant persons, and (ii) in any member state of the European economic area other than the United Kingdom, qualified investors, and will be engaged in only with such persons.

This company presentation may not be used in any jurisdiction where such use is not authorised or is unlawful. The distribution of this company presentation in certain jurisdictions may be restricted by law. Persons in whose possession this company presentation may come are required to inform themselves about and to observe such restrictions.

Each recipient hereof, by virtue of receiving this company presentation, will be deemed to have acknowledged, represented and agreed that it is not a U.S. Person and is acting for its own account or for the account of a non U.S. Person in an offshore transaction (as defined in regulation s under the securities act) and (a) if it is in the United Kingdom, it is a relevant person, and/or a relevant person who is acting on behalf of, relevant persons in the United Kingdom and/or qualified investors to the extent it is acting on behalf of persons or entities in the United Kingdom or the European economic area; or (b) if it is in any member state of the European economic area other than the United Kingdom, it is a qualified investor and/or a qualified investor acting on behalf of, qualified investors or relevant persons, to the extent it is acting on behalf of persons or entities in the European economic area or the United Kingdom.

This company presentation is confidential and is being provided to you solely for your information and may not be reproduced in any form or forwarded or further distributed to any other person or published, in whole or in part, for any purpose whatsoever. Any forwarding, distribution or reproduction of this company presentation in whole or part is unauthorised. Failure to comply with this directive may result in a violation of the securities act or the applicable laws of other jurisdictions.

the provision of this company presentation doesn't constitute or shall not be relied upon as constituting, the giving of investment (or other) advice by the company or any other shareholders, employees representatives or affiliates thereof.

Neither Avangard nor its respective subsidiaries, associates, directors, employees, agents or advisors (such directors, employees, agents or advisors being hereafter referred to as "representatives"), makes any representation or warranty (express or implied) as to the adequacy, accuracy, reasonableness or completeness of the information contained in this company presentation or of any additional information, and such parties or entities expressly disclaim any and all responsibility or liability (other than in respect of fraudulent misrepresentation) based on or relating to the accuracy or sufficiency thereof, or for any errors or omissions from, this company presentation or any additional information or based on or relating to the recipient's reliance or use or the reliance or use by any of its associates or representatives on or of this company presentation or any additional information, or any other written or oral communications transmitted to the recipient or any of its associates or representatives or any other person in the course of its or their evaluation of an investment in the company.

Forward looking statements this company presentation includes statements that are, or may be deemed to be, "forward looking statements". These forward looking statements can be identified by the use of forward looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will" or "should" or, in each case their negative or other variations or comparable terminology. These forward looking statements include all matters that are not historical facts. They appear in a number of places throughout this company presentation and include statements regarding the intentions, beliefs or current expectations of the company. By their nature, forward looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward looking statements are not guarantees of future performance. The company's actual performance, results of operations and financial condition may differ materially from the impression created by the forward looking statements contained in this company presentation.

Subject to its legal and regulatory obligations, Avangard expressly disclaims any obligation to update or revise any forward looking statement contained herein to reflect any change in expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based. Neither troika nor any of its respective affiliates undertake to provide the recipient hereof with access to any additional information or to update this company presentation or to correct any inaccuracies herein which may become apparent.

Any recipient of this company presentation is solely responsible for assessing and keeping under review the business, operations, financial condition, prospects, creditworthiness, status and affairs of the company.

In no circumstances shall the delivery of this company presentation imply that no negative change may occur in the business of the company after the date of issuance of this company presentation, or any date of amendment and/or addition thereto. Financial information and rounding

Certain financial information contained in this company presentation has been extracted from the company's unaudited management accounts and financial statements prepared in accordance with Ukrainian Accounting Standards ("UAS"). The areas in which management accounts or UAS financial statements differ from International Financial Reporting Standards ("IFRS") and/or U.S. Generally accepted accounting principles could be significant and you should consult your own professional advisors and/or conduct your own due diligence for a fuller understanding of the significance of such differences and any impact such differences may have on the relevant financial information contained in this company presentation. Some numerical figures included in this company presentation have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in certain tables may not be an arithmetic aggregation of the figures that preceded them.

Certain information presented herein (including market data and statistical information) has been obtained from various sources which the company considers to be reliable. However, the company makes no representation as to, and accepts no responsibility or liability whatsoever for, the accuracy or completeness of such information.

Table of contents

- AVANGARDCO IPL at a glance
 Business overview
- 3. Financial performance

Appendix: market overview and financial snapshot

1. AVANGARDCO IPL at a glance

Avangardco IPL business highlights

The ongoing military confrontation and economic instability in Ukraine contributed to another challenging quarter for Avangardco.

- In spite of these factors, Avangardco remains the industry leader in Ukraine and one of the leading producers globally*:
- √ 49% share in the industrial production of shell eggs in Ukraine
- ✓ 91% share in the production of dry egg products in Ukraine
- √ 72% share in export of eggs and dry egg products from Ukraine
- Diversified sales channels:
- √ 33% of the Company's total consolidated revenue derived from export
- ✓ Export sales to 37 countries, including new markets of Bangladesh and the UK
- ✓ Main export destinations: MENA, SSA, the Far East, the CIS, the EU
- √ 10% of the Company's total shell egg sales were from export sales
- ✓ Shell egg sales to supermarket chains increased to 38% of the Company's total sales to third parties, while sales through a lower margin wholesale channel declined to 52% in Q1 2015
- √ 65% of the Company's total egg product sales derived from export sales of dry egg products

Key Metrics*

Continued negative impact on the Ukrainian economy resulting from the military conflict:


- ✓ Further devaluation of the Ukrainian Hryvnia against the world currencies
- Sharp decrease in industrial production
- Decrease in retail trade turnover due to the reduced real income of the population
- Real GDP:
 - ✓ 2014 –decrease by 6.8% YoY
 - √ Q1 2015 decrease by 17.6% YoY
- CPI:
- ✓ 2014: 24.9% YoY;
- ✓ April 2015: 60.9% YoY
- Currency devaluation:
 - ✓ 2014 UAH/USD: average 49% YoY;
 - ✓ 2014 UAH/EUR: average 48% YoY
 - √ Q1 2015 UAH/USD: average 138% YoY
 - ✓ Q1 2015 UAH/ EUR: average 96% YoY
- Refinancing rate:
 - 04.03.2015 30.00%
 - 06.02.2015 19.50%
 - 13.11.2014 14.00%
 - 17.07.2014 12.50%
 - 15.04.2014 9.50%
 - √ 31.12.2013 6.50
- Agriculture amounted to 10.3% of GDP in 2014

Industry update*

- Reduced demand for consumer goods due to decline in population's living standards (in April a decrease in retail trade turnover amounted to 29.6% YoY)
- Partial loss of sales market in the Crimea, Lugansk and Donetsk regions (Crimea totalled up to 5% of Ukrainian shell egg consumer market and Donbass and Lugansk regions amounted to 14%)
- Growth in production of shell eggs by households in Ukraine

^{*}According to data from SSCU, NBU, Pro-Consulting, Company data

Facilities overview



🜎 - facilities working at the minimum level of production capacity as located in the areas


close to the conflict zone

One of the largest populations of laying hens in the world*

All facilities are located in 14 of the 24 regions of Ukraine and the Autonomous Republic of Crimea:

- total production capacity of 8.6 bn eggs and 30.1 mn laying hens
- two modern poultry complexes Avis and Chornobaivske with total production capacity of 3.5 bn eggs and 11.2 mn laying hens respectively
- as at 31 March 2015, approximately 64% of laying hens flock is at the Avis and Chornobaivske poultry complexes

Total number of laying hens, mn heads



^{*} According to data from SSCU, Pro-Consulting, Egg Industry Journal (<u>www.WATTAgNet.com</u>)

^{**} excluding impaired facilities in Eastern Ukraine and Crimea with total production capacity of 3.7 mn laying hens and 1.1 bn eggs and farms in the areas close to and in the conflict zone that are working at the minimum level of production capacity. The Company will bring those facilities back into the operation cycle when the situation stabilises.

Operational and financial performance in Q1 2015


Operational performance

Production of shell eggs,


- Total flock (-41%YoY): 20.0 mn heads as at 31 March 2015
- The number of laying hens (-37%YoY): 16.6 mn heads as at 31 March 2015
- Shell eggs production (-44%YoY): 1.051 bn pcs
- Sales of shell eggs to third parties (-16%YoY): 1.067 bn pcs
- Export sales of shell eggs (-33%YoY): 108 mn pcs
- Average shell egg sales price (+60%YoY): 1.07 UAH/egg (excl. VAT)
- Dry egg products produced (-83%YoY): 1.150 th tonnes
- Dry egg product sales (-55% YoY): 3.251 th tonnes
- Average egg product sales price (-26%YoY): 5.24 USD/kg


Financial performance

- Revenue (-52%YoY): USD72.4 mn
- Export revenue (-61%YoY): USD24.0 mn or 33% of total revenue
- EBITDA (-90%YoY): USD6.4 mn
- EBITDA margin: 9%
- Net loss reached USD52.2 mn, incl. losses on exchange USD45.9 mn



Production of egg products,






2. Business overview


Diversification of sales

- Production of shell eggs declined by 44% YoY due to the reduction in the number of laying hens
- 16% YoY decrease in sales of shell eggs to third parties was due to the decline in production volumes and particial loss of sales markets in the Crimea and Eastern Ukraine
- Share of shell egg sales to supermarkets chains increased to 38% from the total sales to 3rd parties
- Sales of Kvochka-branded eggs decreased by 19% YoY due to the decrease in the purchasing power of the population
- Export of shell eggs decreased by 33% YoY due to decrease in production volumes as well as the increased competition between egg producers for export markets
- Export share of shell eggs amounted to 10% of the total shell egg sales to 3rd parties
- Sales of dry egg products declined as well as did export sales due to the strategy to balance sales structure and get rid of inventories

Egg sales to third parties by volume, %



Egg product sales by volume, %



The Company's strategy:

- to expand export sales of shell eggs and dry egg products with the focus on MENA, SSA, the Far East, the CIS and the EU markets
- to expand sales of shell eggs to retail chains and further penetrate the market with Kvochka-branded products

Export strategy in action



• Export to 37 markets

2014-Q1 2015:


4 markets

Denmark


PanamaBangladesh

• UK

 In Q1 2015 the top export markets for shell eggs were Iraq, UAE and Moldova and the top export markets for egg products were Indonesia, Denmark, Turkey, Pakistan and Taiwan




Source: SSCU, International Trade Center, European Commission, Pro-Consulting, Company data



3. Financial performance

Key financial highlights



Key financial highlights

\$'000	Q1 2014	Q1 2015	%	Q4 2014*	Q1 2015	%
Revenue	152,199	72,426	(52%)	74,474	72,426	(3%)
Average shell egg price, UAH/egg	0.67	1.07	60%	0.99	1.07	8%
Average shell egg price, USD/egg Average egg products price	0.076	0.051	(33%)	0.069	0.051	(26%)
USD/kg	7.04	5.24	(26%)	6.41	5.24	(18%)
Cost of sales	(101,729)	(64,203)	(37%)	(59,005)	(64,203)	9%
Cost per egg, UAH/egg	0.44	1.01	130%	0.75	1.01	35%
Cost per egg, USD/egg	0.050	0.048	(4%)	0.052	0.048	(8%)
Cost per egg products, USD/kg	4.56	3.59	(21%)	4.93	3.59	(27%)
Gross profit	59,745	14,610	(76%)	21,608	14,610	(32%)
Net Profit/Loss	46,799	(52,179)	-	(17,812)	(52,179)	-
EBITDA	61,163	6,357	(90%)	23,622	6,357	(73%)
EBITDA margin	40%	9%		32%	9%	

• The decline in revenue was primarily due to the sharp 138% YoY devaluation of the Ukrainian Hryvnia against the US dollar and the significant reduction in the number of laying hens due to the closure of poultry farms in the Crimea and Eastern Ukraine. Additionally, it was affected by the decline in sales volumes of shell eggs and egg products by 16% YoY and 55% YoY as well as the decrease in the average sales price of all the Company's products in dollar terms. However, the decline in the Company's revenue was partially offset by the increase in average sales price of shell eggs and egg products in Hryvnia by 60% YoY and 77% YoY respectively

 As a result of the devaluation cost of sales in the US dollar decreased by 37% YoY, cost per egg by 4% YoY and cost per egg product by 21% YoY, however cost per egg in the Ukrainian hryvnia increased by 130% YoY due to higher prices for fodder and other components


•EBITDA was down by 90% YoY due to decreased revenue together with the increased cost per unit of output in Hryvnia terms as well as the reduction in income from the revaluation of biological assets and inventories of finished goods with the expired shelf life date being written off in the amount of US\$11.1 mn

 Net loss amounted to USD 52.2 mn and included loss on foreign exchange of USD 45.9 mn

A	2013	2014	Δ	1Q14	1Q15	Δ	4Q14	1Q15	Δ
Average FX UAH/USD	7.993	11.910	+49%	8.863	21.116	+138%	14.434	21.116	+46%

^{*}Recalculated from UAH to USD per average quarter FX rate Source: Company data, NBU

Revenue and EBITDA margin bridges




Key segment results

Key financial indicators

	Shell eggs			
USD '000	Q1 2014	Q1 2015	%	
Revenue	95,601	53,885	(44%)	
Export sales, %	20%	18%		
Revenue contribution, %	63%	74%		
Gross profit	35,480	9,610	(73%)	
Gross profit contribution, %	59%	66%		
Gross profit margin, %	37%	18%		

Egg products				Consolidated			
Q1 2014	Q1 2015	%		Q1 2014	Q1 2015	%	
51,326	16,926	(67%)		152,199	72,427	(52%)	
82%	85%			40%	33%	-	
34%	23%						
18,135	5,265	(71%)		59,745	14,610	(76%)	
30%	36%						
35%	31%			39%	20%		

Sales revenue structure by segment



- Revenue share of two main segments (shell eggs and egg products) amounted to 97% of consolidated revenue in Q1 2015
- Export revenue share of two main segments (shell eggs and egg products) reached 33% of the consolidated revenue in Q1 2015
- Revenue in shell eggs segment decreased by 44% YoY as a result of the devaluation of the Ukrainian Hryvnia against the US dollar since approximately 82% of the segment revenue comes from the sales in Ukraine as well as slight decrease in shell egg sales to third parties by 16% YoY
- As a result of the decrease in sales and average sales price of dry egg products, revenues in the dry egg products segment decreased by 67% YoY. The decrease in sales by 55% YoY was due to the decrease in production as well as changes in the sales strategy. The average sales price decreased by 26% YoY due to a reduction in export volumes.


Key segment quarter results

Key financial indicators

	Sh	ell eggs	
USD '000	Q4 2014*	Q1 2015	_ %
Revenue	54,226	53,885	(1%)
Export sales, %	18%	18%	
Revenue contribution, %	73%	74%	
Gross profit	27,432	9,610	(65%)
Gross profit contribution, %	127%	66%	
Gross profit margin, %	51%	18%	


Egg pr	oducts		Cor	nsolidated	
Q4 2014*	Q1 2015	%	Q4 2014*	Q1 2015	%
17,376	16,926	-3%	74,474	72,426	(3%)
93%	85%		35%	33%	
23%	23%				
1,843	5,265	186%	21,608	14,610	(32%)
9%	36%				
11%	31%		29%	20%	

Shell egg sales, bn pcs



^{*}Recalculated from UAH to USD per average quarter FX rate, see sl.13
Source: Company data

Egg product sales, th tonnes



Cost structure

Cost of finished goods breakdown


USD '000	Q4 2014*	Q1 2015	%
Raw materials	46,642	51,779	11%
Payroll of production personnel and related charges	2,585	1,674	(35%)
Depreciation	6,185	6,112	(1%)
Services provided by third parties	3,333	4,524	36%
Other	0,032	0,130	-
Total COGS	58,775	64,102	9%

General administrative and distribution costs breakdown


USD '000	Q4 2014*	Q1 2015	%
Salaries and wages	1,240	853	(31%)
Services provided by third parties	4,056	2,527	(38%)
Transport expenses	1,641	1,501	(9%)
Depreciation	121	86	(29%)
Other expenses	247	173	(30%)
Total GA&D	7,305	5,140	(30%)

^{*}Recalculated from UAH to USD per average quarter FX rate, see sl.13
Source: Company data

Cost of finished goods structure, %




General administrative and distribution costs structure, %



Shell eggs: cost of sales breakdown

Change in cost of sales of shell egg, UAH/egg



Cost of sales of components for shell egg production, UAH/pcs

	Q4 2014	Q1 2015	%
Fodder*	0.47	0.74	0.27
Grains	0.09	0.15	0.06
Oils	0.29	0.43	0.14
Other	0.09	0.15	0.06
Labor	0.03	0.04	0.01
Depreciation	0.02	0.03	0.01
Packing, vitamin	0.04	0.08	0.04
Other	0.2	0.12	(0.08)
Total	0.75	1.01	0.26

The growth of shell egg cost was mainly due to the UAH 0.27/egg increase in fodder costs mainly oils as well as UAH 0.04/egg growth of cost of packing, vitamin etc, prices for which are mainly in US dollars

Price of fodder components, UAH/tonnes

		Q1 2014			Q4 2014			Q1 2015		
		Avangard	Market	%	Avangard	Market	%	Avangard	Market	%
Fodder		2,447	2,514**	3%	3,759	3,890**	3%	5 924	6 219**	(5%)
	Grains	1,269	1,268	0%	1,409	1,601	12%	2 441	2 604	(6%)
	Oils	2,878	3,042	6%	5,264	5,337	1%	7 754	8 232	(6%)
	Other	6,956	-	-	15,965	-	-	24 824		

^{*}In volume terms average receipt of fodder consists of grains (50%), oils (41%) and other (9%)

Source: Company data, APK inform

^{**} Avangard's average receipt, volume terms


Debt structure. Cash and cash equivalents

Debt structure

USD '000	31.12.2014	31.03.2015
Total Debt	343,757	339,286
Long-term loans	79,844	73,828
Current portion of long-term debt	15,190	16,363
Long-term bond liability	0	0
Long-term finance lease (incl. VAT)	88	61
Short-term bond liability	198,635	199,034
Short-term loans	50,000	50,000
Cash and cash equivalents	117,856	89,890
Net Debt	225,901	249,396
Net debt/LTM EBITDA	1.74	3.34

Loan portfolio servicing schedule, USD mn *

- 99% of total debt is held in USD and EUR
- · Loan portfolio structure:
 - USD 73%
 - EUR 26%
 - UAH 1%
- Major debt amounts (excl. Eurobond, leasing and commodity credits) are held in the European banks, such as Landesbank Berlin AG, Deutsche bank AG (London branch), Credit Suisse, Intesa Sanpaolo S.p.A (London branch), Rabobank
- The Company's cash and cash equivalents decreased as a result of the negative cash flow from operating and investing activities
- Cash and cash equivalents are held on the accounts in the European banks




*Excluding. interest


Appendix

Industry leader in Ukraine

Industrial production of shell eggs, bn pcs




Export of shell eggs and egg products from Ukraine, USD mn




Source: Pro-Consulting, Company data

Industrial production of dry egg products, th tonnes




Egg price in Ukraine, UAH / 10 eggs




^{*} Recalculated at average rate of USD to UAH for the period at 21.42

^{**} Recalculated at average rate of USD to UAH for the period, see sl.13


Growth potential for eggs and dry egg products



Breakdown of world imports of eggs and egg products in 2014E, USD mn




^{*} Share of EU imports from non- EU countries is 4%



^{*}Ukraine excl. Crimea. In 2013 share of Crimea in total production of eggs was 3%

Export of eggs and egg products from Ukraine, USD mn



^{**} Key destinations for Avangard export

Balance Sheet

\$'000	2014	Q1 2015	%
NON-CURRENT ASSETS	622,035	417,703	(33%)
Property, plant and equipment	579,922	394,370	
Non-current biological assets	21,637	11,112	
Deferred tax assets	2,489	1,675	
Held to maturity investments	17,959	10,527	
Other non-current assets	28	19	
CURRENT ASSETS	416,292	318,297	(24%)
Inventories	115,896	77,799	
Current biological assets	28,228	26,860	
Trade accounts receivable, net	79,221	84,337	
Prepaid income tax	48	47	
Prepayments and other current assets, net	29,094	16,734	
Taxes recoverable and prepaid	45,949	22,630	
Cash and cash equivalents	117,856	89,890	
TOTAL ASSETS	1,038,327	736,000	(29%)
TOTAL FOLLOW			
TOTAL EQUITY	645,888	346,897	(46%)
NON-CURRENT LIABILITIES	82,178	75,280	(8%)
CURRENT LIABILITIES	310,261	313,841	(1%)
Short-term bond liabilities	198,635	199,034	
Current portion of non-current liabilities	15,368	16,471	
Short-term loans	50,000	50,000	
Trade accounts Payable	6,907	3,497	
Other Payables	39,351	44,839	
TOTAL LIABILITIES	392,439	389,121	(1%)
TOTAL EQUITY AND LIABILITIES	1,038,327	736,000	(29%)
NET DEBT at the date	225,901	249,396	10%

Income Statement

\$'000	2014	Q1 2014	Q1 2015	YoY %
REVENUE	419,618	152,199	72,426	(52%)
Income from revaluation of biological assets at fair value	15,364	9,275	6,387	
Cost of sales	(314,001)	(101,729)	(64,203)	
GROSS PROFIT	120,981	59,745	14,610	(76%)
General administrative expenses	(10,772)	(5,456)	(1,554)	
Distribution expenses	(20,532)	(5,660)	(3,586)	
Income from government grants and incentives	218	68	24	
Impairment of non current assets	(23,589)	-	-	
Income from special VAT treatment	36,490	5,680	4,535	
Other operating income/expenses, net	18,680	343	(13,869)	
OPERATING PROFIT/(LOSS)	84,116	54,720	160	(100%)
Financial income	3,176	39	1,119	
Financial expenses	(44,101)	(7,663)	(7,574)	
Gains/(losses) on exchange	(71,284)	(223)	(45,867)	
PROFIT BEFORE TAX	(28,093)	46,873	(52,162)	(100%)
Income tax expenses	1,175	(74)	(17)	
PROFIT/(LOSS) FOR THE PERIOD	(26,918)	46,799	(52,179)	
EBITDA	129,497	61,163	6,357	(90%)
EBITDA margin	31%	40%	9%	

Cash Flow Statement

\$'000	Q1 2014	Q1 2015
PROFIT BEFORE INCOME TAX	46,873	(52,162)
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	50,758	6,678
(Increase)/decrease in net working capital	(9,640)	(9,496)
Interest paid	(1,681)	(505)
Income tax paid	(28)	(33)
NET CASH GENERATED FROM/(USED IN) OPERATING ACTIVITIES	39,409	(3,356)
Purchases of PP&E	(28,689)	(11,227)
Interest received	39	1,076
Repayment of VAT government bonds	-	2,267
NET CASH GENERATED FROM/(USED IN) INVESTING ACTIVITIES	(28,650)	(7,884)
NET CASH GENERATED FROM/(USED IN) FINANCING ACTIVITIES	14,642	6,258
NET INCREASE/(DECREASE) IN CASH	25,400	(4,982)
Cash at the beginning of the year	156,804	117,856
Effects of translation into presentation currency	(3,732)	(22,984)
Cash at the end of the period	178,472	89,890